Page last updated: 2024-08-23

silybin and crizotinib

silybin has been researched along with crizotinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bosch-Barrera, J; Cuyàs, E; Menendez, JA; Micol, V; Pérez-Sánchez, A	1

Other Studies

1 other study(ies) available for silybin and crizotinib

Article	Year
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell cycle (Georgetown, Tex.), 2016, Dec-16, Volume: 15, Issue:24 Topics: Anaplastic Lymphoma Kinase; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Rearrangement; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Silybin; Silymarin; STAT3 Transcription Factor	2016

Article

Year

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Cell cycle (Georgetown, Tex.), 2016, Dec-16, Volume: 15, Issue:24

Topics: Anaplastic Lymphoma Kinase; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Rearrangement; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Silybin; Silymarin; STAT3 Transcription Factor

2016